We and others have previously demonstrated that (chronic) interleukin (IL)-12 gene therapy delivered intratumorally through ex vivo gene-engineered dendritic cell (DC) is competent to promote the regression of established murine tumors. In this report, we have developed a conditional expression system (rAd.RheoIL12) to determine the temporal requirements of transgenic IL-12p70 production by administered DC on therapeutic outcome in a subcutaneous B16 melanoma model. DCs infected with rAd.RheoIL12 (DC.RheoIL12) secreted IL-12p70 in a tightly regulated fashion in response to a synthetic diacylhydrazine small molecule ligand in vitro, and the treatment benefit of DC.RheoIL12 delivered into B16 lesions was strictly ligand dependent in vivo. Indeed, DC.RheoIL12-based therapy promoted the regression of established day 7 B16 tumor lesions after intratumoral injection, provided that ligand administration occurred within 24 h of DC injection and was sustained for approximately 5 or more days. Treatment efficacy was correlated to the magnitude of systemic anti-B16 CD8 þ T cells cross-primed in vivo, which in turn, appeared dependent on the early enhanced in vivo survival of adoptively transferred DC.RheoIL12 in tumor and tumor-draining lymph nodes. The unique safety feature of DC.RheoIL12 application was emphasized in a combined treatment model with rIL-2, where profound TNF-a-associated toxicity could be ameliorated upon discontinuation of activating ligand administration.
Introduction
Interleukin (IL)-12 remains a promising cancer therapeutic agent based on its potent supportive activity on Type-1 antitumor natural killer (NK), CD4
þ T cells and CD8 þ T cells. 1 However, given the reported toxicity of recombinant human IL-12 (rhIL-12) in patients, 2 and limited sources of GMP-grade rhIL-12 for clinical application, gene therapy approaches may represent safer, more tenable treatment options. Indeed, phase I clinical trials implementing intra-or peritumoral delivery of recombinant viral-based 3, 4 or plasmid-based 5 IL-12 cDNA, or IL-12 gene-modified autologous fibroblasts 6 or dendritic cells (DCs) 7 have been found both safe and well tolerated. However, objective clinical responses in patients with melanoma or a diverse range of carcinomas receiving these gene therapies have been rare, variable (between disease histologies), transient and largely focused at the site of treatment. [3] [4] [5] [6] In cases where disease resolution was partial or complete, increased frequencies of tumor-infiltrating lymphocytes 4, 5 and elevated levels of circulating tumor-specific CD8 þ T cells 5 were observed, consistent with the improved cross-priming of specific immunity in these patients.
The cross-priming of specific T cells appears to be best accomplished by DCs that serve as a natural, but regulated, source of IL-12, 8 with recent reports suggesting the superior preclinical efficacy of DC-based IL-12 gene therapy. [9] [10] [11] In particular, we have shown that intratumoral (i.t.) injection of DCs engineered to produce IL12p70 (through recombinant adenovirus infection) results in the dramatically improved cross-priming of a broadly reactive, tumor-specific CD8 þ T-cell repertoire in concert with tumor rejection in a murine sarcoma model. 11 As this previous system used a recombinant adenovirus encoding mIL-12 under a cytomegalovirus (CMV)-based promoter (rAd.cIL12; Tatsumi et al. 11 ) to engineer DCs, where IL-12p70 production was constitutive, the immunological impact of this cytokine on early (that is, within the tumor lesion) vs late (that is, within tumor-draining lymph nodes (LNs) or the tumor at the time of primed Tcell infiltration) immune events could not be resolved. In an attempt to address this issue, we have developed the novel RheoSwitch Therapeutic System (RTS) that was incorporated into an rAd vector (rAd.RheoIL12) for expression of mIL-12p70, driven off a promoter that is conditionally activated by a small molecule diacylhydrazine ligand. 12 Using this system, we could effectively turn on/off transgene expression in engineered DCs (DC.RheoIL12) after i.t. injection (by regulating ligand administration) and investigate the temporal requirements of ectopic IL-12p70 production for optimal treatment safety and efficacy.
Materials and methods

Mice
Female 6-to 8-week-old C57BL/6 wild-type and C57BL/ 6-TgN(ACTbEGFP)1Osb/J EGFP Tg mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in microisolator cages. Animals were handled under aseptic conditions per protocol approved by an Institutional Animal Care and Use Committee and in accordance with recommendations for the proper care and use of laboratory animals.
Cell lines
The B16 melanoma, MC38 colon carcinoma and EL-4 thymoma H-2 b cell lines, syngeneic to C57BL/6 mice, have been described previously. 13 Cell lines were maintained in conditioned medium (CM; RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and 10 mM L-glutamine; all reagents from Invitrogen, Carlsbad, CA) in a humidified incubator at 5% CO 2 and 37 1C.
Generation of DCs
DCs were generated from murine bone marrow (BM), as previously described. 11 Briefly, wild-type or EGFP Tg mouse BM was cultured in CM supplemented with 1000 U ml À1 recombinant murine granulocyte/macrophage colony-stimulating factor and recombinant mIL-4 (PeproTech, Rocky Hill, NJ) at 37 1C in a humidified, 5% CO 2 incubator for 7 days. CD11c þ DCs were then isolated using specific MACS beads, per the manufacturer's protocol (Miltenyi Biotec, Auburn, CA). CD11c þ DCs produced in this manner were 495% pure based on morphology and coexpression of the CD11b, CD40, CD80 and class I and class II major histocompatibility complex antigens (Ags) (data not shown).
Viral vectors
The control adenoviral vector rAd.c5 and rAd.cIL12, encoding mIL-12 driven off a CMV promoter, were produced and provided by Vector Core Facility of the University of Pittsburgh Cancer Institute and have been described previously. 11 The rAd.RheoIL12 vector was produced in the following manner. The coding sequences for VP16-RXR and Gal4-EcR separated by the encephalomyocarditis virus internal ribosome entry site (IRES) sequence were inserted into the adenoviral shuttle vector under the control of the human ubiquitin C promoter. Subsequently, the coding sequences for the p40 and p35 subunits of mIL-12 separated by IRES sequence, placed under the control of a synthetic inducible promoter, were inserted upstream of the ubiquitin C promoter. The shuttle vector carrying these transcription units for the two fusion proteins and inducible IL-12 subunits was recombined with the adenoviral backbone (AdEasy1; Stratagene, La Jolla, CA) in Escherichia coli BJ5183 cells. After verifying the recombinant clone, the plasmid carrying the rAd.RheoIL12 genome was grown in and purified from XL10-Gold cells, digested off the plasmid backbone and was then packaged by transfection into HEK293 cells. The resulting primary viral stock was amplified by reinfection of HEK293 cells and was purified by CsCl density-gradient centrifugation. In brief, the RTS 12 incorporates two fusion proteins, the DEF domains of a mutagenized ecdysone receptor (EcR) fused with a Gal4 DNA-binding domain and the EF domains of a chimeric RXR fused with a VP16 transcription activation domain, expressed under a constitutive promoter (Figure 1 ). The binding of the small-molecule (pharmacologically inert diacylhydrazine) ligand 12 to EcR causes heterodimerization between the two fusion proteins, forming an active transcription factor that induces expression of the mIL-12 subunit genes placed under the control of an inducible promoter containing Gal4-binding sites. Figure 1 Conditional production of IL-12p70 in dendritic cells (DCs) using a recombinant adenovirus incorporating the RheoSwitch Therapeutic System (RTS). In DCs infected with Ad.RheoIL12 (see Materials and methods section and Tatsumi et al. 11 for construction details), the Gal4-EcR and VP16-RXR fusion proteins are expressed under the constitutive ubiquitin C promoter. These proteins form heterodimers in the presence of the activator ligand, resulting in the conditional activation of mIL-12p70 transcription (from a responsive/inducible promoter). The box labeled 'IL12' represents the IL-12p40 and IL-12p35 coding sequences separated by internal ribosome entry site (IRES). rAd.c5, over a range of multiplicity of infections (MOIs) for 48 h. At various time points after this (0-48 h), DCs were then cultured in the absence or presence of the activating ligand (10-200 ng ml
À1
; Kumar and Katakam 12 ) for an additional 24 h before analysis of IL12p70 secretion using a specific ELISA kit (BD Bioscience, San Diego, CA; lower level of detection ¼ 62.5 pg ml À1 ). In some cases, to discern the stringency of conditional cytokine production, DCs infected with rAd.RheoIL12 (that is, DC.RheoIL12), which had been pretreated for with ligand, were washed free of ligand and cultured in control media for an additional 24 h before analysis of IL-12p70 secretion.
Flow cytometry
For phenotypic analysis of adenovirus-infected DCs, phycoerythrin-conjugated or fluorescein isothiocyanateconjugated mAbs against mouse cell-surface molecules (CD11b, CD11c, CD40, CD54, CD80, CD86, H-
(all from BD Bioscience)) and appropriate isotype controls were used, and flow cytometric analysis was performed using an FACScan (Becton Dickinson, San Jose, CA) flow cytometer. À1 ligand (in 50 ml DMSO) vs DMSO carrier control that were initiated at 0, 24 or 48 h after DC administration, as indicated. After initiation, mice received a total of five consecutive daily i.p. injections of activator ligand at this dose. In additional experiments, ligand was administered beginning on the day of DC injection and then terminated 1, 3 or 5 days after DC injection to discern whether early cessation of IL-12p70 transgene promotion reduced the therapeutic benefits of this approach. In all cases, tumor size was assessed every 3 or 4 days and recorded in mm 2 by determining the product of the largest perpendicular diameters measured by vernier calipers. In indicated experiments, animals rendered tumor-free (45 days) after therapy were rechallenged with the B16 melanoma (10 5 cells injected on the left flank, that is, contralateral to the original B16 challenge site) and MC38 colon carcinoma (10 5 cells on the right flank) cells to discern the presence and specificity of memory immunity in these mice. All data are reported as the average tumor area ± s.d. All animal cohorts contained five mice per group.
B16 tumor model
Imaging of injected DCs
To assess the fate and function of injected DCs, we generated day 7 BM-derived, CD11c
þ DCs from C57BL/ 6-TgN(ACTbEGFP)1Osb/J EGFP Tg mice. EGFP þ
CD11c
þ DCs were left uninfected or they were infected with rAd viruses, as indicated above. At 48 h after infection, 1 Â 10 6 control or virally infected DCs were harvested, washed in PBS and injected into day 7 B16 tumor lesions established in syngeneic B6 mice. Three days after DC injection, tumors and draining inguinal LNs were resected, fixed for 1 h in 2% paraformaldehyde (in PBS) and then cryoprotected in 30% sucrose in PBS before being shock frozen in liquid nitrogen-cooled isopentane. Frozen sections (5 mm) were then generated and counterstained with 2 mg ml À1 Hoechst 33258 (SigmaAldrich, St. Louis, MO) for 3 min. The washed sections were then mounted in Gelvatol (Monsanto Chemical Co., St. Louis, MO) and observed using an Olympus BX51 microscope equipped with a cooled charge-coupled device color camera.
Assessment of specific CD8
þ T-cell responses against B16 melanoma Pooled CD8
þ T cells were isolated to a purity of 495% from the spleens of two treated mice per group 25 days after tumor inoculation using magnetic bead cell sorting (MACS; Miltenyi Biotec) and then cocultured (1 Â 10 5 per well) with 1 Â 10 4 irradiated (100 Gy) B16 or EL-4 tumor cells. After 48 h incubation, culture supernatants were collected and analyzed for interferon (IFN)-g release using a commercial ELISA (BD Bioscience) with a lower limit of detection of 31.5 pg ml À1 . Data are reported as the mean ± s.d. of triplicate determinations.
Toxicity model
The ability to ameliorate toxicity associated with DC.RheoIL12-based treatment through agonist ligand removal was assessed in an IL-2 coadministration model based on a report by Carson et al.
14 Female 6-to 8-weekold C57BL/6 wild-type mice (n ¼ 5 mice per group) were injected i.p. with 10 6 DC.RheoIL12 (or control DC.c5) and cotreated with daily i.p. injections of rhIL-2 (3 Â 10 5 IU per day in PBS; PeproTech) or PBS. Activating ligand (30 mg kg À1 per day in 50 ml DMSO) was injected i.p. daily beginning on the day of DC administration for up to 7 days as indicated. Mice were monitored daily for toxicity. In addition, peripheral blood was obtained daily through tail-vein venipuncture for analysis of serum tumor necrosis factor (TNF)-a levels using a commercial ELISA (eBioscience; San Diego, CA) with a lower limit of detection of 8 pg ml
À1
, per the manufacturer's instructions.
Statistical analyses
All experiments were analyzed as previously described, 11 with comparisons yielding P-values o0.05 considered significant.
Results
Murine BM-derived DCs infected with Rheo-IL12 conditionally produce high levels of IL-12p70 when treated with ligand in vitro DCs cultured from C57BL/6 (B6) mouse BM for 7 days in the presence of rmIL-4 and rmGM-CSF were left untreated or infected at various MOIs with control rAd.c5, rAd.cIL-12 (encoding mIL-12p70 under a constitutive CMV promoter) or rAd.RheoIL12 (encoding IL-12p70 under a conditional promoter responsive to the small molecule ligand; Figure 1) . At 48 h after infection, DCs were cultured in the absence or presence of ligand for an additional 24 h, at which time culture supernatants were harvested for quantitation of IL-12p70 production by ELISA. As shown in Figure 2 , control uninfected DCs or DCs infected with Ad.c5 in the absence or presence of exogenous drug failed to produce elevated levels of IL-12p70 when compared with DCs infected with rAd.cIL12 (DC.cIL12). DCs infected with rAd.RheoIL-12 (DC.RheoIL12) only produced IL-12p70 after treatment with activating ligand. On the basis of the results of 'criss-cross' experiments, we observed that optimal infected DC production of IL-12p70 appears to occur using an MOI of 100, with cells treated with 50-100 ng ml À1 activating ligand (Figure2a and data not shown). Delayed provision of ligand to DC.RheoIL12 for up to 48 h did not result in any significant reduction in IL-12p70 production when compared to addition of ligand at the 0 h time point in vitro (Figure 2b) . Finally, removal of ligand acutely silenced the ability of DC.RheoIL12 (previously activated by ligand) to continue to produce elevated levels of IL-12p70 in vitro (Figure 2b ). Figures 3a and b , the treatment of mice with ligand alone or DC.RheoIL12 in the absence of ligand failed to yield any therapeutic benefit. In marked contrast, tumors treated with DC.cIL12 or DC.RheoIL12 (in concert with a 5-day course of ligand administration) regressed in size over the following 3 weeks, following ligand activation within 24 h of DC injection (Figures 3a and b) . Indeed, these therapies were statistically indistinguishable based on tumor size measurements, and yielded 100% (5 of 5 mice) tumor regression rates in each of these instances. Interestingly, if ligand administration was delayed until 48 h after i.t. DC injection (at a time point when this agent can still efficiently induce IL-12p70 production from DC.RheoIL12 in vitro, that is, Figure 2b) , DC.RheoIL12-based therapy resulted in only slight inhibition of tumor growth rate (Po0.05 for all time points after day 10), and all animals exhibited progressive lesions that required killing by day 30. This suggests that therapeutic benefit of i.t. DC.IL12 treatment is dependent upon IL-12p70 production at early time points (occurring presumably within the tumor lesion and/or draining LNs).
Intratumoral administration of DC
Additional experiments were performed in which activator ligand was administered to DC.RheoIL12 injected mice for 1, 3 or 5 days after DC injection (Figures 3c and d) . The results of these studies suggest that early termination of ligand administration impacts the antitumor efficacy of i.t.-delivered DC.RheoIL12, with inhibition of tumor growth limited or ablated if ligand is not provided to mice for approximately 5 or more days after provision of gene-modified DCs. These findings are consistent with data provided in Figure 2b , and support the tight (ligand-dependent) regulation of therapeutic impact resulting from injected DC.RheoIL12 in this model. Furthermore, when taken together, the results depicted in Figure 3 strongly suggest that optimal anti-melanoma efficacy associated with i.t. delivery of DC.RheoIL12 results from provision of the ligand during the day 1-5 period after DC injection into B16 tumors. Delayed activation of conditional DC.RheoIL12 therapy appears ineffective due to the apparent failure of injected DCs to survive in vivo Our previous report 10 suggested that IL-12 gene insertion into DCs promotes the enhanced survival of these cells after injection into the tumor microenvironment and the consequent capacity of these cells to cross-prime antitumor CD8 þ T cells and conceivably recruit circulating effector T cells into the tumor microenvironment in vivo. Hence, we next attempted to discriminate whether unsuccessful DC-RheoIL12 therapy initiated (by i.p. ligand administration) 48 h after DC injection was due to the inability of DCs to persist in the tumor microenvironment, the inability of these cells to traffic to tumor-draining LN and/or the inability of specific
CD8
þ T cells to be cross-primed as a result of treatment. Experiments as outlined in Figure 3a were recapitulated, with two mice per cohort killed 72 h after i.t. injection of DCs, with the exception that EGFP Tg (H-2 b ) mice were used as the source of BM for DC generation. Tumor and LN were resected and tissue sections prepared for analysis of EGFP þ DCs by fluorescence microscopy. The remaining three animals per cohort were followed until day 25, when they were killed and pooled splenocytes isolated for analysis of B16-specific CD8 þ T-cell responses.
As depicted in Figure 4 , the ability to resolve EGFP Conditional IL-12 gene therapy H Komita et al DC.cIL12 and DC.RheoIL12 could be readily observed in B16 lesions, and were seen more rarely within draining LNs, in mice injected i.t. with DC.cIL12 or DC.RheoIL12 (if activating ligand was provided i.p. at 0 or 24 h after DC administration). Very few or no EGFP þ DCs were detectable in tissues harvested from mice treated with control (uninfected) DC or DC.RheoIL12 (where ligand administration was delayed for 48 h after DC injection). When comparing the tissues isolated from mice treated with DC.RheoIL12 and ligand provided at 0 vs 24 h, there were more EGFP þ DCs in both the tumor (P ¼ 0.001) and tumor-draining LN (P ¼ 0.02) when the activating drug was provided earlier.
Therapeutic benefits of DC.RheoIL12 administration are associated with the induction of specific CD8 þ T cells and durable antitumor immunity Given the apparent dependency of injected DCs vitality on the timing of ligand injection, we would have predicted a superior degree of specific CD8 þ T-cell cross-priming in the case of mice receiving DC.RheoIL12 activated on day 1 vs later time points by activator ligand. Interestingly, although this was certainly observed for the DC.RheoIL12 treatment cohorts in which ligand was provided for days 1-5 vs days 3-7, it was not the case when comparing these cohorts receiving ligand on days 1-5 vs days 2-6 (Figure 5a) . Indeed, the in vitro splenic CD8 þ T-cell responses (IFN-g secretion) against relevant B16 vs irrelevant EL-4 tumor targets was comparable for both of these cohorts, and these each approximated that detected in mice treated with DC.cIL12. Overall, these anti-B16 CD8 þ T-cell response profiles appeared to directly correlate with the therapy outcome (Figure 3a) .
To address whether effective DC.RheoIL12-based therapy was associated with the development of durable antitumor immunity, animals rendered tumor-free as a consequence of therapy were (re)challenged with relevant B16 melanoma cells or irrelevant MC38 colon carcinoma cells on day 45 (after initial B16 challenge). As shown in Figure 5b , all mice previously cured of their melanomas exhibited specific protection against B16 tumor cells, whereas, MC38 tumor lesions grew progressively.
Discontinuation of the administration of activating ligand mitigates IL-12-associated toxicity in vivo Conceptually, a major safety benefit in the therapeutic use of DC.RheoIL12 (vs DC.cIL12) is the ability to silence cytokine production in vivo upon discontinuation of activating ligand administration. On the basis of reported lethality of treating wild-type B6 mice with rIL-2 þ rIL-12, 14 we developed a cotreatment model in which B6 mice were administered rIL-2 and either DC.RheoIL12 or control DC.cIL12 (as sources of IL-12). Consistent with the report of Carson et al.,
14 treatment of mice with single agents ( ± ligand) or rIL-2 þ DC.RheoIL12 (in the absence of ligand) proved safe (Figure 6a ). In contrast, cotreatment with rIL-2 þ DC.cIL12 or DC.RheoIL12 (activated by ligand coinjection) proved highly toxic (Figure 6a ). However, discontinuation of ligand administration before day 5 of rIL-2 þ DC.RheoIL12 cotreatment reduced such toxicity (Figure 6b ), in concert with a normalization of serum TNF-a levels (Figure 6c ).
Discussion
The application of cytokine gene therapy for the treatment of cancer has attracted significant attention over the past 15 years, largely owing to the possibility of providing paracrine production of an immunological 19, 20 but even more so, when applied in the context of gene-modified DCs. [9] [10] [11] To date, however, human phase I trials of IL-12 gene therapy implementing plasmids or viral vectors have failed to achieve durable, objective clinical responses in the cancer setting. [3] [4] [5] [6] 19 DC-based IL-12 gene therapy has thus far only been attempted in a single phase I trial, in which i.t. injection of 1-5 Â 10 7 DCs infected with adenovirus encoding IL-12p70 was investigated in 17 patients with colorectal, hepatic or pancreatic carcinoma. 7 In this phase I trial, treatment was deemed well tolerated (with the notable therapy-associated adverse events being lymphopenia (grade 1-3) and fever (grade 1-2) occurring in 65-76% of patients) and effective in promoting 1 partial response (pancreatic carcinoma) and stabilization of disease in 2 patients with hepatocellular carcinoma. 7 Given residual concerns that are both clinical (that is, unanticipated toxicities associated with DC-based IL-12 gene therapy and potential IL-12-dependent limitations in therapeutic DC.IL12 migration after i.t. administration) and basic (that is, when is IL-12 production in transduced DCs most important for therapeutic efficacy) in nature, we have developed a conditional IL-12 gene therapy model in the current report. This model allows for delayed turn-on of IL-12p70 production by injected DCs (at a time when these cells may have acquired tumor Ags and migrated to tissuedraining LNs) and/or turn-off of IL-12p70 production at any consequent time (that is, when toxicity might be observed in patients).
Using this conditional DC.RheoIL12 gene therapy in the aggressive B16 melanoma model in C57Bl/6 mice, we suggest the following conclusions: (1) elevated levels of IL12p70 are only secreted from DC.RheoIL12 in the presence of the activating ligand and is silenced upon ligand removal; (2) i.t. DC.RheoIL12-based therapy is as effective as i.t. DC.cIL12-based therapy when ligand is administered to tumor-bearing animals within 24 h of DC injection and activation is sustained for approximately 5 or more days; (3) IL-12 transgene expression in DCs appears to prolong the survival of these cells in the tumor microenvironment and is associated with higher numbers of i.t. injected DCs that migrate to tumor-draining LNs; (4) the strongest immune correlate to therapy outcome is the level of tumorspecific CD8 þ T cells cross-primed by the therapy and not the number of injected DCs sustained in the tumor microenvironment; and (5) animals rendered free of disease by DC.RheoIL12-based therapy exhibit durable protective immunity against B16 melanoma rechallenge.
These data suggest the continued investigation of i.t.-delivered DC.IL12-based gene therapy in the clinical setting, focusing on the objective clinical response as a primary study end point, and cross-primed antitumor Conditional IL-12 gene therapy H Komita et al CD8 þ T cells (producing IFN-g) as a secondary study end point. Although significant differences were not observed in tumor regression and the activation of tumor-specific CD8 þ T cells as a consequence of treatment with DC.RheoIL12 (activated by the ligand within 24 h of injection) vs DC.cIL12, the ability to turn transgene IL-12 expression on and off in vivo offers additional safety and potential therapeutic control to this treatment modality (in that both the timing and level of IL-12 expression may be regulated by the administration of ligand). This may be most salient in prospective therapies integrating the combined use of multiple cytokines (such as IL-2 þ IL-12 or IL-12 þ IL-18) to further optimize the induction of clinically beneficial Type-1 antitumor immunity, where the risk of collateral toxicities may be anticipated. 14, 21 Given these considerations, we are currently developing a phase I clinical trial implementing i.t.-delivered DC.RheoIL12 gene therapy for patients with accessible, advanced stage melanoma at the University of Pittsburgh.
